Every 424B that Edesa Biotech, Inc. (EDSA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow EDSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EDSA filings page.
Edesa Biotech, Inc. (EDSA) is conducting a follow‑on offering of 3,870,500 common shares and, for certain investors in lieu of shares, pre‑funded warrants to purchase up to 675,000 common shares, together with common share warrants to purchase up to 4,545,500 common shares.
The securities are priced at a combined public offering price of $5.50 per common share and accompanying warrant (or $5.4999 per pre‑funded warrant and accompanying warrant), for total gross proceeds of $25.0 million and underwriting discounts of $1.5 million. Estimated net proceeds are about $23.1 million, to be used for general corporate purposes including working capital, R&D and manufacturing.
The common share warrants are exercisable at $7.50 per share and expire on the earlier of 18 months after issuance or 30 days following public announcement of Phase 2 vitiligo topline data for EB06. The pre‑funded warrants are immediately exercisable at $0.0001 per share and do not expire. The offering will dilute new investors by $3.28 per share relative to the $5.50 offering price.
Edesa Biotech, Inc. (EDSA) plans a primary offering of common shares, pre-funded warrants and common share warrants under an effective shelf registration. Each common share (or pre-funded warrant) will be sold together with an accompanying common share warrant, with all securities issued separately but purchased together.
The company expects to use net proceeds for general corporate purposes, including working capital, capital expenditures, and research and development and manufacturing expenses. As of June 30, 2026, Edesa Biotech had 9,633,223 common shares outstanding and net tangible book value of $6.9 million, or $0.72 per share, and discloses that investors in this offering will experience dilution relative to this book value.
Edesa Biotech, Inc. is registering up to 729,241 common shares for resale by existing investors who acquired these shares in a June 2026 private placement. This is a resale registration only; Edesa will not receive any proceeds from sales made under this prospectus, though it has borne the registration costs.
In the private placement, institutional and accredited investors, including the chief executive officer, purchased an aggregate of $3.5 million of common shares at $4.69 per share for outside investors and $5.21 per share for the CEO. Edesa previously stated it intends to use those net proceeds to advance its vitiligo program and its respiratory drug candidate paridiprubart, and for working capital and general corporate purposes.
Edesa is a biopharmaceutical company focused on inflammatory and immune-related diseases, with programs in medical dermatology (including vitiligo and allergic contact dermatitis) and respiratory conditions such as acute respiratory distress syndrome. As of June 17, 2026, it had 9,633,223 common shares outstanding and listed its common shares on the Nasdaq Capital Market under the symbol EDSA.
The company whose common shares trade on Nasdaq under the symbol EDSA is updating its at-the-market offering so it may sell up to $2,262,508 of common shares from time to time through H.C. Wainwright & Co. as sales agent. This amount reflects the limits of General Instruction I.B.6 of Form S-3, which caps annual sales at one-third of public float for issuers with less than $75,000,000 held by non-affiliates. As of October 24, 2025, the public float was $19,273,618, based on 7,034,167 common shares held by non-affiliates at $2.74 per share. During the 12 months prior to this supplement, the company sold $4,162,030.62 of its securities under this rule, including $3,718,324.61 under the prior prospectus and $837,134 under an earlier prospectus supplement.